← Back to Company DatabaseVisit Website
Insitro
Machine learning-driven drug discovery and development.
Series C+South San Francisco, CAFounded 2018
About
Insitro integrates machine learning with high-throughput biology to accelerate drug discovery and development. The company uses human-derived cellular models and large-scale data generation to build predictive models of disease, including cancer. Founded by Stanford professor Daphne Koller, insitro has partnerships with major pharmaceutical companies.
Total Funding
$700MKey Product
ML-driven drug discovery platformGeography
North AmericaKey Investors
a16zARCH Venture PartnersCanada Pension Plan Investment Board
Focus Areas
Drug DiscoveryAI / Machine Learning
Technology
AI / Machine LearningGenomics / Sequencing
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026